Contents

1. Financial Review and Business Updates
2. Strengths
3. Pharmaceutical
4. Med Tech
5. Healthcare Services
6. Appendix
Financial Review and
Business Updates
1H23 Financial Review (1/2)

Revenue

RMB 21,395 million (+0.22% YoY)

- Sustained revenue growth from new launches, including Serplulimab Injection (PD-1), Trastuzumab Injection (HER2), Avatrombopag Maleate Tablets and others
- Revenue contribution from Azvudine
- Sales of COVID-19 related products, including mRNA COVID-19 Vaccine, COVID-19 Antigen and Nucleic Acid Test Kits, declined significantly.

Revenue Excluding COVID-19 Related Products

Approximately +15% YoY

- Sustained revenue growth from new launches, including:
  - Serplulimab Injection (PD-1) revenue RMB 556 million
  - Trastuzumab Injection (HER2) revenue +57.1% YoY
  - Avatrombopag Maleate Tablets revenue +32.7% YoY
  - Netupitant and palonosetron hydrochloride capsules, Adalimumab Injection (TNF-α), Bevacizumab Injection (VEGF) and others

R&D Expenditure

RMB 2,884 million (+19.77% YoY)

- R&D Expense RMB 2,134 million (+16.80% YoY)
- Investment in innovative drugs and biosimilars, innovation & incubation platforms, early-stage projects, etc.
- Pharma R&D Expenditure RMB 2,519 million (+22.16% YoY), accounting for 15.75% of Pharma revenue; Pharma R&D Expense RMB 1,792 million, accounting for 11.20% of Pharma revenue

Net Profit Attributable to Shareholders

RMB 1,777 million (+15.74% YoY)

- 1H23 one-off gain was RMB 405 million, mainly due to the fair value changes in financial assets, including YSB, and net effect of Tianjin Pharma partial disposal

Net Profit After One-off Gain

RMB 1,373 million (-26.28% YoY)

- COVID-19 related products revenue declined significantly, but there are still expenses related to teams, medical affairs, marketing, etc.
- Controlled subsidiary Gland Pharma experienced intensified competition in the U.S. market. Penem production line shut down as part of capacity expansion plan.
- The increase of interest-bearing debt and foreign exchange losses from US$ interest hikes and US$ appreciation
- Management and R&D expenses increased YoY

Net Operating Cash Flow

RMB 1,810 million (+0.63% YoY)

Note: new launches are innovative products launched in the past few years.
### Expense Structure (RMB million)

<table>
<thead>
<tr>
<th></th>
<th>1H23</th>
<th>1H22</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>21,395</td>
<td>21,348</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>10,697</td>
<td>9,770</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>50.0%</td>
<td>45.8%</td>
</tr>
<tr>
<td>Selling and Distribution</td>
<td>5,071</td>
<td>4,175</td>
</tr>
<tr>
<td>Ratio</td>
<td>23.7%</td>
<td>19.6%</td>
</tr>
<tr>
<td>Gross Margin minus Selling and Distribution Expense Ratio</td>
<td>26.3%</td>
<td>26.2%</td>
</tr>
<tr>
<td>Administrative</td>
<td>2,045</td>
<td>1,679</td>
</tr>
<tr>
<td>Ratio</td>
<td>9.6%</td>
<td>7.9%</td>
</tr>
<tr>
<td>R&amp;D</td>
<td>2,134</td>
<td>1,827</td>
</tr>
<tr>
<td>Ratio</td>
<td>10.0%</td>
<td>8.6%</td>
</tr>
<tr>
<td>Finance</td>
<td>545</td>
<td>262</td>
</tr>
<tr>
<td>Ratio</td>
<td>2.5%</td>
<td>1.2%</td>
</tr>
</tbody>
</table>

### Key Influencing Factors
- Sustained revenue growth from new launches. Sales of COVID-19 related products declined significantly, but Azvudine contributed to the revenue.
- The proportion of new launches in the total revenue has increased.
- Expenses related to COVID-19 related products: sales of COVID-19 related products declined significantly, but there are still expenses related to teams, medical affairs, marketing, etc.
- Overseas market expenses: Prelaunch investment of Serplulimab Injection (PD-1) in the U.S.; controlled subsidiary Sisram expense has risen with the increase in direct sales business and the appointment of brand ambassador to enhance brand awareness.
- Investment in establishing and strengthening sales teams for new launches, including Serplulimab Injection (PD-1), Keverprazan Hydrochloride, etc.
- Remained stable, YoY increase of 0.1 percentage points.
- Increased labor cost.
- Newly acquired company.
- Consulting expenses for projects to be acquired.
- Investment in innovative drugs and biosimilars, innovation & incubation platforms, early-stage projects, etc.
- The increase of interest-bearing debt and foreign exchange losses from USD interest hikes and USD appreciation.

### Key Indicators

<table>
<thead>
<tr>
<th></th>
<th>1H23</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Bank Balances</td>
<td>14,885</td>
<td>16,241</td>
</tr>
<tr>
<td>(RMB million)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net Asset Attributable to Shareholders</td>
<td>45,460</td>
<td>44,582</td>
</tr>
<tr>
<td>(RMB million)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current Ratio</td>
<td>1.00</td>
<td>1.06</td>
</tr>
<tr>
<td>Quick Ratio</td>
<td>0.79</td>
<td>0.85</td>
</tr>
<tr>
<td>Debt-to-Asset Ratio</td>
<td>50.6%</td>
<td>49.5%</td>
</tr>
</tbody>
</table>
## 1H23 Business Updates (1/2)

### Launched Product

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Details</th>
</tr>
</thead>
</table>
| **Serplulimab Injection (PD-1)** | - 1H23 revenue RMB556 million  
- Approved for ES-SCLC in March, the world first PD-1 inhibitor approved for 1L ES-SCLC  
- The MAA of ES-SCLC was accepted by the EMA in March |
| **Aregensu® (Second-Generation Aretensanum Injection)** | - PO qualified by WHO in June, registered and approved in 16 countries |
| **Keverprazan Hydrochloride#** | - The first domestic self-developed potassium-competitive acid blocker (P-CAB) was approved in February, for the treatment of duodenal ulcer (DU) and reflux esophagitis (RE) |
| **Telpegfilgrastim Injection#** | - Approved in June, long-lasting recombinant human granulocyte colony-stimulating factor product for reducing the infections expressed in form of febrile neutropenia in patients with non-myeloablative cancer when receiving treatment |
| **Etelcalcetide Hydrochloride Injection#** | - Approved in May, for the treatment of Secondary hyperparathyroidism (SHPT) adult patients receiving hemodialysis treatment for chronic kidney disease (CKD) |
| **Sacubitril Valsartan Sodium Tablets** | - Approved in August, the world first approved breakthrough innovation generic with innovative crystalline form for chronic heart failure |
| **Axicabtagene Ciloleucel** | - Approved for 2L r/r LBCL in June |
| **Apremilast Tablets** | - Included in the 2023 National Reimbursement Drug List (NRDL) in January; approved for psoriasis in 2021 |
| **Netupitant and Palonosetron Hydrochloride Capsules** | - Included in the 2023 National Reimbursement Drug List in January; approved in 2019 for the prevention of acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy in adult patients |

### Product Pipeline

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Details</th>
</tr>
</thead>
</table>
| **Trastuzumab Injection (HER2)** | - 1H23 revenue increased 57.1%YoY  
- The BLA for breast cancer and metastatic gastric cancer indications was accepted by the FDA in February |
| **RT002 (long-lasting DaxibotulinumtoxinA botulinum toxin)#** | - The NDA for 1) aesthetic indication (moderate to severe glabellar lines and 2) "medical indication (cervical dystonia) were accepted in April and July respectively. |
| **Tenapanor (NHE3 small molecule)#** | - The NDA for controlling hyperphosphatemia in adult patients receiving hemodialysis treatment for chronic kidney disease (CKD) was accepted in July*. |
| **FS-1502 (HER2-ADC)#** | - Initiated Ph3 clinical trial for HER2-positive locally advanced or metastatic breast cancer in March |
| **13-Valent Pneumococcal Conjugate Vaccine** | - Completed the enrollment of the Ph3 clinical trial in April, for active immunization in individuals 2 months of age and older |
| **FCN-159 (MEK small molecule)** | - Two indications 1) treatment of histiocytic tumors, 2) "treatment for adult patients with NF1 (neurofibromatosis type I) related plexiform neurofibroma who are unable to undergo surgery or encounter postoperative residual/recurrence, were included in the Breakthrough Therapy Designation in April and in July, respectively. |

---

**Note**: Subsequent Events  
**Note#:** License-in products
Established Scientific Advisory Board (SAB) to assist in formulating and optimizing the medium- to long-term scientific innovation and R&D strategies, and to provide additional strategic guidelines and insights, serving as external think tank.

The first SAB meeting was held in June. Members of the SAB discussed and evaluated the global R&D strategies, product pipelines and R&D resources allocation. Members offered valuable suggestions on development goals of products at early stage, global innovative strategies and external collaboration.

Clinical and commercial value oriented, making Go/No-Go decision on key decision points (GT1-GT6) for R&D projects from phases through target selection to marketing, significantly increased the efficiency of R&D management and clinical operations.

Establishing an innovative pharmaceutical team in the United States to cover medical affairs, market access, sales, etc., and collaborating with Syneos Health to support the U.S. commercialization of Serplulimab Injection (PD-1).

Granting the exclusive development and commercialization rights for Rituximab Injection (CD20) in 16 emerging markets in Asia and Africa to Boston Oncology in April; expanded the collaboration scope with KGbio on Serplulimab Injection (PD-1) to 12 countries in the Middle East and North Africa from the original 10 countries in Southeast Asia in August.

For controlled subsidiary Sisram, the proportion of direct sales revenue increased from 65% in 1H22 to 72% in 1H23; acquired PhotonMed in June to build direct sales aesthetic medical team in China and to further promote the brand.

Controlled subsidiary Gland Pharma fully acquired Cenexi and entered into Europe-based CDMO in April.

Constructing the Côte d’Ivoire Industrial Park with R&D, manufacturing and distribution capabilities, localizing products manufacturing and distributing in the future.

FDA conducted Pre-License Inspection at controlled subsidiary Henlius Songjiang 1st Plant on Trastuzumab Injection (HER2) in August*.

FDA conducted Pre- Approval Inspection at controlled subsidiary Guilin Pharma on Sertraline Hydrochloride Tablets and Compound Sulfamethoxazole Tablets in August*.

FDA conducted GMP Inspection at 3 facilities of Gland Pharma

Sustained revenue growth from new launches, including Serplulimab Injection (PD-1), Trastuzumab Injection (HER2), Avatrombopag Maleate Tablets and others.

The JV Intuitive Fosun has received approval from the NMPA for "Thoracic and Abdominal Endoscopy Surgical Control System" in June, marking the forthcoming launch of domestically-manufactured Da Vinci Surgical Robot; the Manufacturing R&D Center is under construction to support localized manufacturing and global commercialization in the future.

Note*: Subsequent events
Strengths
Encourage and guide the development of first-tier pharmaceutical companies

Volume Based Procurement (VBP)
Procurement frequency increased and category expanded, including biosimilar, medical devices, diagnostics, etc.

Precision Pipeline Management

Dynamic Adjustment of NRDL
Released 2022 NRDL in January 2023 with a record high success rate and a moderate price decline than last year

Global Operation

Corporate Governance
Launch innovative product abroad

DRG/DIP ongoing payment reform

R&D
CDE released the Guidelines of Clinical Value-Oriented Clinical Development for Anti-tumor Drugs (Draft for Comments) in July 2021 to encourage innovative drug development

Upgraded Innovative Pipeline & System Development

Encourage and guide the development of first-tier pharmaceutical companies

Lean Management System

Constructing internationally competitive asset structure and building organizational capabilities with forward-looking industry insights and operation experiences

Collaboration, Win-win, Internationalization, Innovation Driven Growth, Efficiency Improvement

Strengths of the Group

Industry background
In a constantly evolving industry, Fosun Pharma has accomplished dozens of M&A and license-in agreements by leveraging forward-looking insights.

Fosun Pharma will continuously capture development opportunities in the industry and access innovative therapeutic areas, products, and technologies to achieve sustainable organic growth.

Differentiated Innovation

- **In-house R&D & Incubation**
  - Acquisitions of Wanbang, Yaoyou, and Guilin Pharma
  - Formed Henlius
  - Formed Fochon
  - Acquired Alma, specialized in EBD
  - Acquired Gland Pharma
  - Acquired Tridem Pharma
  - Formed Fosunlead

- **Investment & M&A**
  - Acquired Adgenvax
  - Integrated Aleph Biomedical
  - Launched Bevacizumab
  - Acquired Alma, specialized in EBD
  - Formed Fusion
  - Launched Adalimumab
  - Formed Fosun Health Capital

- **License-in**
  - Acquired Gland Pharma

- **Collaboration**
  - Formed Fosunlead
  - Launched Rituximab
  - Launched Trastuzumab

- **2002-2004**
  - Founded

- **2007-2009**
  - Implemented Innovative Policies

- **2013**
  - Formed Intuitive Surgical with Intuitive Surgical
  - Formed Fosun Kite with Kite Pharma

- **2015**
  - Initiated VBP, accelerated industry evolving
  - Avatrombopag Tablet

- **2017**
  - Formed Fusion
  - Launched Rituximab
  - Launched Trastuzumab

- **2018-2019**
  - Initiated VBP, accelerated industry evolving
  - Avatrombopag Tablet

- **2020**
  - Implemented Innovative Policies

- **2021**
  - Akynzeo Aloxi Anamorelin
  - Keverprazan Hydrochloride
  - Apremilast Parsabiv
  - Azvudine Tablet

- **2022**
  - Launched Serplulimab
  - Gland Pharma acquired Cenexi, a European CDMO in April 2023

- **2015**
  - Implemented Innovative Policies

- **2018-2019**
  - Initiated VBP, accelerated industry evolving
  - Avatrombopag Tablet

- **2020**
  - Implemented Innovative Policies

- **2021**
  - Akynzeo Aloxi Anamorelin
  - Keverprazan Hydrochloride
  - Apremilast Parsabiv
  - Azvudine Tablet

- **2022**
  - Launched Serplulimab
  - Gland Pharma acquired Cenexi, a European CDMO in April 2023

- **2015**
  - Implemented Innovative Policies

- **2018-2019**
  - Initiated VBP, accelerated industry evolving
  - Avatrombopag Tablet

- **2020**
  - Implemented Innovative Policies

- **2021**
  - Akynzeo Aloxi Anamorelin
  - Keverprazan Hydrochloride
  - Apremilast Parsabiv
  - Azvudine Tablet

- **2022**
  - Launched Serplulimab
  - Gland Pharma acquired Cenexi, a European CDMO in April 2023
Established Scientific Advisory Board (SAB) to assist in formulating and optimizing the medium- to long-term scientific innovation and R&D strategies, and to provide additional strategic guidelines and insights; the SAB has in total 9 members, comprising of globally renowned academicians, scientists and clinical experts with outstanding academic attainments from China and overseas, with area of expertise covering oncology, cardiovascular, immunology, clinical medicine development and other fields.

Optimizing R&D decision-making mechanisms; making Go/No-Go decision on key decision points (GT1-GT6) for R&D projects from phases through target selection to marketing, significantly increased the efficiency of R&D management and clinical operations.
### Approved Products

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rituximab Injection (CD20)</td>
<td>First biosimilar in China</td>
</tr>
<tr>
<td>Trastuzumab Injection (HER2)</td>
<td>First China-developed mAb biosimilar approved both in China and in the EU</td>
</tr>
<tr>
<td>Serplulimab Injection (PD-1)</td>
<td>First self-developed innovative anti-PD-1 monoclonal antibody (mAb)</td>
</tr>
<tr>
<td>Axicabtagene Ciloleucel</td>
<td>First CAR-T cell therapy approved in China</td>
</tr>
<tr>
<td>Avatrombopag Maleate Tablets</td>
<td>First oral drug approved for the treatment of thrombocytopenia related to chronic liver diseases in the world</td>
</tr>
<tr>
<td>Apremilast Tablets</td>
<td>First oral PDE4 inhibitor for the treatment of plaque psoriasis in China</td>
</tr>
<tr>
<td>Netupitant and Palonosetron Hydrochloride Capsules</td>
<td>The world’s first dual-channel antiemetic</td>
</tr>
</tbody>
</table>

### Late-Stage Products

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serplulimab Injection (PD-1)</td>
<td>2023 - 2024</td>
</tr>
<tr>
<td>Trastuzumab Injection (HER2)</td>
<td>First self-developed innovative anti-HER2 monoclonal antibody (mAb)</td>
</tr>
</tbody>
</table>

### 2019 - 2022 Products

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axicabtagene Ciloleucel</td>
<td>Approved for 2L r/r LBCL</td>
</tr>
<tr>
<td>Avatrombopag Maleate Tablets</td>
<td>WHO PQ qualified, registered and approved in 16 countries</td>
</tr>
<tr>
<td>Apremilast Tablets</td>
<td>The NDA for controlling hyperphosphatemia in adult patients receiving hemodialysis treatment for chronic kidney disease (CKD) was accepted by the NMPA</td>
</tr>
<tr>
<td>Netupitant and Palonosetron Hydrochloride Capsules</td>
<td>The NDA for 1) aesthetic indication (moderate to severe glabellar lines and 2) *medical indication (cervical dystonia) were accepted by the FDA</td>
</tr>
<tr>
<td>Fortacin Spray (Lidocaine Proparacaine Spray)</td>
<td>For the treatment of premature ejaculation in Ph3 clinical trial</td>
</tr>
</tbody>
</table>

### Note: 2023 Progress

- Serplulimab Injection (PD-1): The world first PD-1 inhibitor approved for 1L ES-SCLC
- Keverprazan Hydrochloride: First domestic self-developed potassium-competitive acid blocker (P-CAB) for the treatment of duodenal ulcer (DU) and reflux esophagitis (RE)
- Telpegfilgrastim Injection: Long-lasting recombinant human granulocyte colony-stimulating factor product for reducing the infections expressed in form of febrile neutropenia in patients with non-myeloablative cancer when receiving treatment
- Axicabtagene Ciloleucel Injection: Approved for 2L r/r LBCL
Integrated Manufacturing and Improved Operational Efficiency

International Standard Manufacturing

- **Henlinus Xuhui Plant** received both China and EU GMP certification
- **FDA conducted Pre-License Inspection** at Henlius Songjiang 1st Plant on Trastuzumab Injection (HER2) in August*
- **FDA conducted Pre-Approval Inspection** at Guilin Pharma on Sertraline Hydrochloride Tablets and Compound Sulfamethoxazole Tablets in August*
- Constructing the **Côte d'Ivoire Industrial Park** with R&D, manufacturing and distribution capabilities, localizing products manufacturing and distributing

- 10+ production lines for API and formulation of Yao Pharma, Wanbang and Guilin Pharma received GMP certifications from the U.S., Europe, etc.
- **FDA conducted GMP Inspection** at 3 facilities of Gland Pharma
- **Gland Pharma** received GMP certifications from the U.S., EU, Japan, Australia, etc.

From API to Formulation

- Integrating manufacturing facilities to improve efficiency, accelerating the construction of Xuzhou Industrial Park Formulation Plant and of API facilities in Changsha, Xuzhou and Chongqing
Global Operation

- Gland Pharma fully acquired Cenexi and entered into Europe-based CDMO

**Aesthetic Medical Platform Sisram:**
- Strengthened global direct sales teams, improved market control and launched high-margin products drives gross margin from 57% in 1H22 to 61% in 1H23
- 10 direct sales markets including US, UK, Dubai, etc.; acquired PhotonMed in June to build direct sales aesthetic medical team in China and to promote the brand
- The proportion of direct sales revenue increased from 36% in 2016 to 66% in 2022 and further to 72% in 1H23

**Generic Drugs:**
- Gland Pharma Dexrazoxane for Injection is approved in Chinese Mainland in February 2023; filed several other products in Chinese Mainland
- Focusing on complex injectables and expanding to biologics CDMO
- Over 200 people in local branded generics team and growing

**Innovative Drugs:**
- 11 combination therapies with Serplulimab Injection (PD-1) are in global multi-center clinical trials; initiated head-to-head bridging study for ES-SCLC in the U.S.
- Establishing an innovative pharmaceutical team in the United States to cover medical affairs, market access, sales, etc., and collaborating with Syneos Health to support the U.S. commercialization of Serplulimab Injection (PD-1)

Note: 2023 Progress

Figure number: GS(2016)1666
Corporate Governance - Sustainable Development

MSCI-ESG Rating

- **A** in 2023
- **BBB** in 2021
- **BB** in 2020

**Environment**
- Established EHS Committee to continuously improve EHS policies and set the 2nd EHS five-year strategic goals (2021-2026)
- Invested RMB1.15 million in special fund for water conservation in 2022, with a total annual water saving of 337,806 m³, 3.2% of the total annual water consumption

**Social**
- Well-established systems for R&D, product quality management, staff training, social welfare and supply chain management
- Launched 2 orphan drugs/drugs for rare diseases, Aminohexanoic acid powder and Avatrombopag Maleate Tablets; increased the accessibility of Axicabtagene Ciloleucel (CAR-T) through commercial insurances and citizen insurances; provided antimalarial series to Africa and supplied over 300 million doses of artesunate for injection across the world; the second-generation artesunate injection Argesun® received WHO PQ

**Governance**
- Exhibition: 2023 Progress

**Green growth and sustainable development**
- Received A in 2023 MSCI ESG rating, leading the industry*
- Received A- in 2023 HSI/HKQAA ratings, topped in industry
- Included in the HSCASUS, HSCASUSB, and HSMHSUS

**Improvement of product accessibility and affordability, taken the interest of stakeholders into consideration**
- Published over 10 documents related to corporate governance on the official website
- Upheld the professional, branded, digital and compliant marketing system control

**Strengthen corporate governance with ESG to achieve sustainable development**
- Established ESG Committee at the Board level; the independent Anti-Corruption Supervision Department (ACSD) designed a comprehensive anti-corruption system
- Published over 10 documents related to corporate governance on the official website

Note*: Subsequent Events
Note1*: by the end of June 2023
Note: 2023 Progress
**Pharma - Performance**

### Segment Revenue

<table>
<thead>
<tr>
<th>Segment</th>
<th>Revenue (RMB million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1H22</td>
<td>14,327</td>
</tr>
<tr>
<td>1H23</td>
<td>15,995</td>
</tr>
</tbody>
</table>

1.64% YoY

### Segment Results

<table>
<thead>
<tr>
<th>Segment</th>
<th>Results (RMB million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1H22</td>
<td>1,890</td>
</tr>
<tr>
<td>1H23</td>
<td>1,660</td>
</tr>
</tbody>
</table>

-12.17% YoY

### Segment Profit

<table>
<thead>
<tr>
<th>Segment</th>
<th>Profit (RMB million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1H22</td>
<td>1,573</td>
</tr>
<tr>
<td>1H23</td>
<td>1,422</td>
</tr>
</tbody>
</table>

-9.60% YoY

### R&D Expenditure & Expense

<table>
<thead>
<tr>
<th>Year</th>
<th>Total R&amp;D Expenditure (RMB million)</th>
<th>Total R&amp;D Expense (RMB million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1H22</td>
<td>2,399</td>
<td>1,818</td>
</tr>
<tr>
<td>1H23</td>
<td>2,884</td>
<td>2,134</td>
</tr>
</tbody>
</table>

19.77% YoY & 16.80% YoY

### Pharma R&D Expenditure and Expense

<table>
<thead>
<tr>
<th>Year</th>
<th>Pharma R&amp;D Expenditure (%)</th>
<th>Pharma R&amp;D Expense (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1H22</td>
<td>20.19%</td>
<td>19.77%</td>
</tr>
<tr>
<td>1H23</td>
<td>22.16%</td>
<td>19.77%</td>
</tr>
</tbody>
</table>

### Pharma - Performance

- **1H23 Pharma R&D expenditure was RMB2,519 million (+22.16% YoY), accounts for over 85% of the total R&D expenditure and 15.75% of the Pharma revenue; Pharma R&D expense was RMB1,792 million, accounts for 11.20% of the Pharma revenue.**
- **Over 70 innovative drugs (indications) and self-developed biosimilar (indications) pipeline projects by the end of June 2023.**
- **Applied 54 Pharma patents, including 2 U.S. applications, 2 PCT applications; 34 licensed invention patents in 1H23.**

---

**Note 1:**
- Sustained revenue growth from new launches, including Serplulimab Injection (PD-1), Trastuzumab Injection (HER2), Avatrombopag Maleate Tablets and others;
- Revenue contribution from Azvudine;
- Sales of COVID-19 related products, including mRNA COVID-19 Vaccine, COVID-19 Antigen and Nucleic Acid Test Kits, declined significantly.

**Note 2:**
- Segment results are obtained as segment revenue less costs of sales, selling and distribution expenses, administrative expenses and R&D expenses.
- **Note 3:**
  - Sales of COVID-19 related products declined significantly, but there are still expenses related to teams, medical affairs, marketing, etc.;
  - Gland Pharma experienced intensified competition in the U.S. market.
  - Penem production line shut down as part of capacity expansion plan.

**Note 4:**
- Investment in innovative drugs and biosimilars, innovation & incubation platforms, early-stage projects, etc.

---

1H23 Pharma R&D expense increased RMB301 million YoY.
Pharma Key Progress - Serplulimab Injection (PD-1)

The first PD-1 inhibitor approved for 1L SCLC

1H23 Revenue

RMB556 million

2022 Revenue RMB340 million (Launched for 9 months)

Approved Indications in Chinese Mainland
• MSI-H
• sqNSCLC
• ES-SCLC

Overseas Progress
• SCLC was granted with Orphan drug Designation from FDA and EC
• Initiated ES-SCLC head-to-head bridging in the U.S.
• The MAA of ES-SCLC was accepted by the EMA

Outstanding Results
• Serplulimab + chemo (ES-SCLC) randomized, double-blind, median progression, global multi-center Ph3 clinical data: Median OS 15.4 months, vs 10.9 month with placebo; 2 year OS rate 43.1%, vs 7.9% with placebo
• The clinical data have been published in world’s top medical journals including The Journal of the American Medical Association (JAMA), Nature Medicine and British Journal of Cancer

Quick Market Access and Accelerated Market Penetration
• Commercialization team of about 550 people in China; completed tenders on procurement platforms in 29 provinces, autonomous regions and municipalities; covered 35% of the top 110 hospitals
• Establishing an innovative pharmaceutical team in the United States and collaborating with Syneos Health to support the U.S. commercialization of Serplulimab Injection (PD-1)
• Expanded the collaboration scope with KGbio on Serplulimab Injection (PD-1) to 12 countries in the Middle East and North Africa* from the original 10 countries in South Asia in August

Target: PD-1

Note: *Subsequent Events
Note: 2023 Progress
**Pharma Key Progress - Axicabtagene Ciloleucel**

- Axicabtagene Ciloleucel is an innovative **one-time treatment** cell therapy, delivering **lasting relief to patients** and significantly **improving their long-term survival**
- A study published in the *American Society for Transplantation and Cellular Therapy (ASTCT)* compared Axicabtagene Ciloleucel **2L r/r LBCL** treatment with standard treatment. The study shows that treatment with Axicabtagene Ciloleucel can improve **patient survival rates**, **extend progression-free survival**, thereby **reducing the burden on patients**, conserving **healthcare resources**, and offering **superior cost-effectiveness** compared to standard treatment in terms of pharmacoeconomics.

### Indication Expansion

- Approved **2L r/r LBCL** in June 2023
- First **CAR-T** cell therapy product approved in China

### Expanding market potential

- LBCL is the most common subtype of NHL. LBCL accounts for **45.8%** of all NHL in China, **over 40,000 new cases** of LBCL annually, and nearly **13,000 cases are considered refractory or have experienced a relapse**

### Commercialization

- Treated over **500 patients** with **over 140 treatment centers** covering more than **25 provinces and cities** by the end of June 2023; **10,000 m² GMP commercial manufacturing facility**
- Diversified payment methods: included in **over 60** commercial insurances and **90 citizen insurances** by the end of June 2023

### Product Pipeline

- The **Second indication r/r iNHL**, including **FL and MZL** was granted **Breakthrough Therapeutic Designation** by the NMPA in August 2021; **r/r FL** is in the **clinical stage** in China
- FDA approved Tecartus (Brexucabtagene Autoleucel) for the treatment of **r/r MCL** in July 2020; Fosun Kite has completed the technology transfer; **r/r MCL** is in the **clinical stage** in China; **r/r ALL** is in the **clinical trial initiation stage** in China

### Efficacy

<table>
<thead>
<tr>
<th></th>
<th>3L</th>
<th>China RWS</th>
<th>2L</th>
</tr>
</thead>
<tbody>
<tr>
<td>bORR</td>
<td>82%</td>
<td>83%</td>
<td>83%</td>
</tr>
<tr>
<td>bCR</td>
<td>58%</td>
<td>58%</td>
<td>65%</td>
</tr>
<tr>
<td>OS</td>
<td>43% (5 years)</td>
<td>84% (1 year)</td>
<td>55% (4 year)</td>
</tr>
</tbody>
</table>

- The r/r NHL real-world efficacy of multicenter clinical trial in China aligns with global data, with **12-month overall survival rate at 84.3%**, **bORR at 83.2%**, **bCR at 58.4%**, and a **better safety result**

**Note**: Axicabtagene Ciloleucel is recommended by domestic and overseas authoritative guidelines. Treatment on patients with **2L DLBCL** is recommended by National Comprehensive Cancer Network (NCCN) Guidelines in the U.S., National Health Commission Guidelines, Chinese Medical Association Guidelines and Chinese Society of Clinical Oncology (CSCO) Guidelines. Treatment on patients with **2L DLBCL** received category I recommendation from the NCCN Guidelines in the U.S. and from the CSCO

**Note 2023 Progress**
Pharma Segment Commercialization Team

- **Domestic Team**
  - Market Access
  - Oncology Innovative Drug
  - Non-Oncology Innovative Drug
  - OBM Broad Market Team
  - New Retail Team for OTC

- **Overseas Team**
  - Africa
  - India
  - The U.S. and Other Markets

  - U.S. generic drugs team collaborated with 5 major wholesalers and 16 GPOs
  - Establishing an innovative pharmaceutical team in the U.S. to cover medical affairs, market access, sales, etc.

Compliance Marketing

- **Management System**
  - Established strict review and supervision procedures across different departments to ensure marketing compliance

- **Policy Management**
  - Continuously strengthen the internal audit of responsible marketing; audit of compliance management pertaining to the execution of responsible marketing policies, sales procedures, signing of sales contracts, etc. in controlled subsidiaries

- **Employee Training**
  - Enhanced the openness and transparency of the management system by disclosing a number of internal regulation policies on the official website in January 2023, clarifying the bottom line, strictly prohibiting any bribery activities, and committing to building a fair and clean business environment

- **Employee Training**
  - Provided regular responsible marketing training to all employees in marketing-related positions, covering laws and regulations, internal regulations, product knowledge, etc., to ensure reasonable and compliant marketing activities

  - Organized ESG Culture Month, covering training on marketing compliance, anti-corruption and other topics to enhance employees’ understanding and recognition of compliance and awareness of risk management and control

Note: 2023 Progress
Segment Revenue

<table>
<thead>
<tr>
<th>1H22</th>
<th>1H23</th>
</tr>
</thead>
<tbody>
<tr>
<td>4,043</td>
<td>2,218</td>
</tr>
</tbody>
</table>

-45.14% YoY

Segment Result

<table>
<thead>
<tr>
<th>1H22</th>
<th>1H23</th>
</tr>
</thead>
<tbody>
<tr>
<td>440</td>
<td>56</td>
</tr>
</tbody>
</table>

-87.27% YoY

Segment Profit

<table>
<thead>
<tr>
<th>1H22</th>
<th>1H23</th>
</tr>
</thead>
<tbody>
<tr>
<td>699</td>
<td>114</td>
</tr>
</tbody>
</table>

-83.69% YoY

**Aesthetic Field**
- As the core medical aesthetic platform, Sisram’s business covers energy based medical aesthetic devices, injectables, home use devices, aesthetic dentistry

**Respiratory Care**
- Breas develops the home/hospital used respiratory devices; Vivo 1, 2 and 3 ventilators were approved in China in 1H23, continuously expanding in the Chinese market while developing in the European and American markets

**Professional Medical Device & Consumables**
- The domestic medical device registration of “thoracic and abdominal endoscopy surgical control system” was approved by NMPA in June (the fourth generation of Da Vinci Surgical System)
- Others including negative pressure ambulances, portable CT, etc.

**Fosun Diagnosis**
- Actively integrating the operation; business covering immunodiagnostics, biochemical diagnosis, microbial diagnosis, molecular diagnosis, POCT, etc.
- Improving R&D and manufacturing capabilities of diagnostic API, reagents and instruments to provide comprehensive solutions to clients
- Reagents products, including hepatitis B quantitative virus nucleic acid test kit (PCR-Fluorescence probe method), myocardial calcium T test kit (Chemical luminescence), brain sodium peptide test kit (Chemical luminescence) and new devices, including F-A7000 Series assembly line system and chemistry immunoassay integrated analyzer were launched in 1H23

**Note 1:** mainly due to the decrease in the revenue from COVID-19 antigen and nucleic acid test kits, and the decreased overseas sales of third party personal protective products for COVID-19. Revenue excluding COVID-19 related products increased by 8.99% YoY.

**Note 2:** segment results are obtained as segment revenue less costs of sales, selling and distribution expenses, administrative expenses and R&D expenses

Note: 2023 Progress
Medical Devices – Sisram Medical

Establishing global Wellness Ecosystem based on energy based devices and extending to injectables, aesthetic dentistry and personal care

**Financial Performance**

<table>
<thead>
<tr>
<th>1H23 Revenue</th>
<th>1H22 Revenue</th>
</tr>
</thead>
<tbody>
<tr>
<td>174.5 USD million</td>
<td>171.6 USD million</td>
</tr>
</tbody>
</table>

-1.71% YoY

-8.50% YoY

1H23 New Launches

- **Soprano Titanium™**
- **Alma Opus™**
- **BeautiFill™**
  - **LipoSense™**
  - **CellFie™**
- **Alma Veil™**

**Energy-based Devices**

**EBD**

The world’s leading supplier of energy-based aesthetic medical devices

Launched innovative products including Soprano, ThermoLift, Harmony, BeautiFill by LipoLife, etc.

**Personal Care**

**HUD**

New brand for personal care

New brand LMNT for home use devices

Launched the first home use device LMNT One

**Aesthetic Dentistry**

- **B2B2C**
- **B2C, D2C**

**Injectables Expansion through collaboration**

- Products including hyaluronic acid moisturizing product Profhilo and the first long lasting DaxibotulinumtoxinA product RT002
- Invested in new technologies including silk fibroin-sodium hyaluronate products, fat removal product JS-001, etc.

**Strengthening the Global Direct Sales Channel**

Direct sales revenue accounts for 72% of the total revenue in 1H23 (66% in 2022, 36% in 2016) with direct sales channel covers 10 markets globally

- Acquired PhotonMed in June to build direct sales aesthetic medical team in China and to further promote the brand
- Built new direct sales team in Dubai in February 2023 to develop and increase brand awareness in the Middle East; built new direct sales team in the UK to support the strong demand growth for product and services in Europe

**Flagship platform for hair removal Soprano Titanium™ and skin resurfacing and face tightening platform Alma Opus™ are launched in new markets**

FDA regulatory clearance for two complementary accessories of BeautiFill™ system intended for laser assisted liposuction and skin:

- **LipoSense™**: a smart fiber and adipose tissue delivery system intended to increase the safety of procedure by real-time measurement of the treated area temperature
- **CellFie™**: a complementary kit for closed-loop processing of micro fragment adipose tissue for re-injection in medical procedures involving harvesting, concentrating and transferring of autologous adipose tissue harvested with a lipoplasty system
- **Alma Veil™**: targets a wide range of common dermatological and vascular conditions

Note: 2023 Progress
### Localization Process

**2017**
Announced to form a joint venture with Intuitive Surgical in China in 2016 based on the long-term partnership and established **Intuitive Fosun in Shanghai in 2017**

**2019**
Marketing the 4th generation Da Vinci XI Surgical System

**2020**
Da Vinci Surgical System test drives in more than 10 cities across China, with more than 800 doctors from nearly 200 hospitals participated in the experience

**Da Vinci Innovation Center** opened with 1,700 m² of space to provide high-quality hands-on precision medicine training to approximately 4,000 doctors per year

**2021**
Building da Vinci Surgical **Manufacturing R&D Center** in Shanghai, covering about 31.2 acres

**2023**
Domestic medical device registration of “thoracic and abdominal endoscopy surgical control system” was approved by NMPA, marking the forthcoming **launch of domestically-manufactured Da Vinci Surgical System**

**Future**
Localization in technology, manufacturing and services

### Main Products

**Da Vinci Surgical System**
- 34 da Vinci Surgical Systems were installed in China in 1H23; by the end of 1H23, over 330 Systems were installed in Chinese Mainland, Hong Kong and Macau regions; trained over 1,100 doctors
- By the end of 1H23, 8,042 systems were installed worldwide, with more than 55,000 doctors trained to use the system, and performed over 10 million surgeries

**Ion Endoluminal System**
- The robotic-assisted bronchoscopy platform, Ion, was approved by FDA in 2019
- The Ion guided lung nodule biopsy clinical feasibility trial completed enrollment at Shanghai Chest Hospital in October 2021. It is the first clinical trial using Ion excluding the United States

---

**Made in China**
**Joint R&D**
**Global Commercialization**
Healthcare Services
Healthcare Service - Performance

**Segment Revenue**

<table>
<thead>
<tr>
<th>Period</th>
<th>Revenue (RMB million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1H22</td>
<td>2,918</td>
</tr>
<tr>
<td>1H23</td>
<td>3,130</td>
</tr>
</tbody>
</table>

\[7.27\% \text{ YoY}\]

**Segment Result**

<table>
<thead>
<tr>
<th>Period</th>
<th>Result (RMB million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1H22</td>
<td>-387</td>
</tr>
<tr>
<td>1H23</td>
<td>151</td>
</tr>
</tbody>
</table>

+RMB236 million YoY

**Segment Profit**

<table>
<thead>
<tr>
<th>Period</th>
<th>Profit (RMB million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1H22</td>
<td>-442</td>
</tr>
<tr>
<td>1H23</td>
<td>-268</td>
</tr>
</tbody>
</table>

+RMB174 million YoY

**Investment 2011-2017**
- Built offline healthcare network
- Gained experience in high-end healthcare
- Launched online healthcare services
- Developed regional medical centers

**Operation 2018-2020**
- Created advantageous specialty areas
- Online and offline strategic synergy
- Developed high-end aesthetic medical business
- Constructing specialties for health and wellness

**Strategic Upgrade 2021 to date**
- Integrating resources to build Internet healthcare ecosystem
- Consolidating the leading position as non-public healthcare provider
- Building intelligent Cloud Healthcare
- Building healthcare ecosystem

Note 1: offline hospitals revenue recovery
Note 2: segment results are obtained as segment revenue less costs of sales, selling and distribution expenses, administrative expenses and R&D expenses
Note 3: offline hospitals revenue recovery and online business optimization
Healthcare Services - Medical Services

- Focus on the Yangtze River Delta, the Greater Bay Area and other regions; 6,448 beds in total; 9 Internet hospital license; integrated online and offline healthcare services
- Foshan Chancheng Hospital received JCI certification and ranked the TOP1 non-public hospital in China for 5 consecutive years
- 1H23 Foshan Chancheng Hospital became the first medical institution in Foshan designated by the “Measure of using HK registered drugs and medical devices used in HK public hospitals in Guangdong-Hong Kong-Macao Greater Bay Area”; Shanghai Xingchen Children’s Hospital opened and specialized in gynecology and pediatrics

Pearl River Delta

Regional flagship hospitals include Foshan Chancheng, Shenzhen Hengsheng, etc.
- Class III General Hospital with 1,750 beds
- Realized revenue of RMB2,145 million, and profit of RMB111 million in 2022
- Fosun Pharma currently holds 87.41% of the share
- Class III General Hospital with 600 beds
- Acquired 60% share of Shenzhen Hengsheng Hospital for RMB909 million in November 2017

Other Strategic Region

- Class III General Hospital with 800 beds and over 900 doctors and employees
- Acquired 70% share of Guangdong Xinshi Hospital in January 2022

Note1: controlled by the group, last update on 30th June 2023
Note2: according to Ailibi ranking
Note: 2023 Progress
In the post-COVID-19 pandemic era, the pharmaceutical distribution segment has achieved rapid growth with the further normalization of medical services and the continuous improvement of the concentration of industry. The 1H23 revenue from the pharmaceutical distribution business was RMB225.43 billion (+14.71% YoY).

Actively followed the policy direction of updating and upgrading of medical devices and seized the trend change of “expansion of quality medical resources and balanced regional layout” to effectively strengthen the integrated management of internal centralised procurement and supply chain and continuously improve the business scale and network coverage. The 1H23 revenue from the medical device business was RMB62.95 billion (+17.27% YoY), maintaining a high growth rate.

Continued to focus on the change of C-side demand, and created a full-scenario, full-cycle and full-channel business model that integrates online and offline, and continued to promote the rapid development of retail business. The 1H23 revenue from retail pharmacy business was RMB17.70 billion (+15.86% YoY).
<table>
<thead>
<tr>
<th>No.</th>
<th>Therapeutic Area</th>
<th>Product Name</th>
<th>Product Description</th>
<th>Product Picture</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Anti-tumor and immune modulation</td>
<td><strong>Rituximab Injection (CD20)</strong></td>
<td>The medicine was approved by the NMPA in February 2019, and is the first domestic biosimilar. The approved indications include: (1) non-Hodgkin's lymphoma, (2) chronic lymphoblastic leukaemia, (3) rheumatoid arthritis. It is also the first rituximab approved for RA indications in China.</td>
<td>![Product Picture]</td>
</tr>
<tr>
<td>2</td>
<td>Anti-tumor and immune modulation</td>
<td><strong>Trastuzumab Injection (HER2)</strong></td>
<td>The medicine is the first trastuzumab biosimilar approved in China and also the first domestic monoclonal antibody biosimilar approved in both China and Europe. The approved indications include: (1) HER2-positive early breast cancer, (2) metastatic breast cancer, and (3) metastatic gastric cancer. Collaborating with international renowned biopharmaceutical enterprises including Accord Healthcare Limited, PT Kalbio Global Medika and Laboratorio ELEA Phoenix S.A., to supply Europe, the United States, Canada and numerous emerging countries. The medicine has been approved for launch in around 40 countries and regions. The trade name in Europe is Zecepac, while trade name in Australia is Tuzucip and Trastucip.</td>
<td>![Product Picture]</td>
</tr>
<tr>
<td>3</td>
<td>Anti-tumor and immune modulation</td>
<td><strong>Serplulimab Injection (PD 1)</strong></td>
<td>The medicine (PD-1 inhibitor) was approved by the NMPA in March 2022, and is the first self-developed innovative monoclonal antibody. The approved indications include: (1) microsatellite instability-high (MSI-H) solid tumors (conditionally approved), (2) squamous non-small cell lung cancer, (3) extensive-stage small cell lung cancer. It is the first anti-PD-1 monoclonal antibody drug approved for the first-line treatment of small cell lung cancer in the world. It has been recommended by 9 guidelines in 2023, including CSCO Guidelines on Small Cell Lung Cancer Treatment, CSCO Guidelines on Non-Small Cell Lung Cancer Treatment, CSCO Guidelines on Esophageal Cancer Treatment, CSCO Guidelines on Colorectal Cancer Treatment and CSCO Guidelines on Clinical Application of Immune Checkpoint Inhibitors.</td>
<td>![Product Picture]</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td><strong>Adalimumab Injection</strong></td>
<td>The medicine was approved by the NMPA in December 2020, and is the first domestic adalimumab biosimilar with both China and Europe approved GMP certified manufacturing site. The approved indications include: (1) rheumatoid arthritis, (2) ankylosing spondylitis, (3) psoriasis, (4) uveitis.</td>
<td>![Product Picture]</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td><strong>Avatrombopag Maleate Tablets</strong></td>
<td>The medicine was approved by the NMPA in April 2020 and is the first oral drug approved worldwide for the treatment of thrombocytopenia associated with chronic liver diseases. The approved indication is the selective thrombocytopenia treatment of adult patients with chronic liver disease undergoing diagnostic procedures or surgery. In addition, the NDA of the second indication for the treatment of chronic immune thrombocytopenia (ITP) in adults patients with poor response from prior treatment was accepted by the NMPA.</td>
<td>![Product Picture]</td>
</tr>
</tbody>
</table>

Note*: license-in product
<table>
<thead>
<tr>
<th>No.</th>
<th>Therapeutic Area</th>
<th>Product Name</th>
<th>Product Description</th>
<th>Product Picture</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>Anti-tumor and immune modulation</td>
<td>Apremilast Tablet*</td>
<td>The medicine was approved by the NMPA in August 2021, and is the world’s first oral phosphodiesterase-4 (PDE4) inhibitor for the treatment of plaque psoriasis. The approved indication is treatment for adult patients with moderate to severe plaque psoriasis who are suitable for phototherapy or systematic treatment.</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td>Netupitant and Palonosetron Hydrochloride Capsules*</td>
<td>The medicine was approved by the NMPA in August 2019, and is the world’s first dual-channel fixed-dose combination oral compound preparation that simultaneously blocks both NK-1 receptors and 5-HT3 receptors. The approved indication is prevention of acute and delayed nausea and vomit arising from highly emetogenic chemotherapy in adult patients.</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Anti-tumor and immune modulation</td>
<td>Telpegfilgrastim Injection*</td>
<td>The medicine (new generation of long-lasting recombinant human granulocyte colonystimulating factor product) was approved by the NMPA in June 2023, and is classified as class 1 new drug in China. The approved indication is reduction of occurrence of infections expressed in form of febrile neutropenia in patients with non-myeloablative cancer when receiving myelosuppression antitumor drug treatment which can easily cause febrile neutropenia.</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td>Rabbit Anti-Human T-Lymphocyte Immunoglobulin*</td>
<td>The product is a polyclonal antibody inhibitor. The approved indication in Chinese mainland include the prevention of acute transplant rejection in patients receiving solid organ transplantation (SOT) and the treatment of acute rejections if the therapeutic effect of corticosteroid treatment has proven to be unsatisfactory.</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td>Axicabtagene Ciloleucel (Product of JV Fosun Kite)</td>
<td>The product was approved by the NMPA in June 2021, and is the first CAR-T cell therapy product approved for domestic launch. The approved indications include (1) treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r DLBCL) after prior second-line or higher systemic therapy, (2) treatment of adults patients with large B-cell lymphoma (r/r LBCL) that is refractory to first-line immunochemotherapy or that relapses within 12 months of first-line immunochemotherapy (conditional approved).</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Metabolism and Alimentary System</td>
<td>Glutathione Series</td>
<td>The series include Atomolan (glutathione tablets) and Atomolan (glutathione for injection), both of them are class B drug under National Medical Insurance Drug Catalogue and the basic medicine for liver diseases. In particular, Atomolan (glutathione tablets) is the first glutathione oral preparations in China, while Atomolan (glutathione for injection) is the first generic drug of its kind in China.</td>
<td></td>
</tr>
</tbody>
</table>

Note*: license-in product
## Appendix - Core Innovative Products Launched (3/3)

<table>
<thead>
<tr>
<th>No.</th>
<th>Therapeutic Area</th>
<th>Product Name</th>
<th>Product Description</th>
<th>Product Picture</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Metabolism and Alimentary System</td>
<td>Etelcalcetide Hydrochloride Injection*</td>
<td>The medicine (new generation of calcimimetic) was approved by the NMPA in May 2023. The approved indication is treatment of secondary hyperparathyroidism (SHPT) of adult patients receiving hemodialysis treatment for chronic kidney disease (CKD).</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td>Keverprazan Hydrochloride Tablets*</td>
<td>The medicine (potassium ion competitive acid blocker (P-CAB)) was approved by the NMPA in February 2023. The product is the only approved P-CAB with DU/RE double indications and is classified as class 1 new drug in China. The approved indications include duodenal ulcer (DU) and reflux esophagitis (RE).</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Anti-Infection</td>
<td>Antimalarial Series Including Artesunate</td>
<td>The series include Artesun (artesunate for injection), SPAQ-CO (sulfadoxine pyrimidine dispersible tablets + amodiaquine dispersible tablets) and the DARTEPP series (dihydroartemisinin-piperaquine phosphate tablets) etc. In particular, artesunate is the first class 1 new drug in China. Fosun Pharma has a total of 33 antimalarial drugs (including APIs and preparations) with WHO PQ. The second generation of artesunate for injection (Artesun) obtained WHO PQ in June 2023, and was registered and approved in 16 countries. As of June 2023, Fosun Pharma has supplied over 300 million doses of artesunate for injection across the world.</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td>Azvudine Tablets*</td>
<td>The medicine (broad-spectrum RNA virus inhibitor) obtained the emergency conditional approval from the NMPA in July 2022 for use in treatment of adult patients suffering moderate COVID-19. The approved indication also includes treatment for adult HIV-1 patients (AIDS patients) with high viral load in combination with other reverse transcriptase inhibitors (conditionally approved).</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td>mRNA COVID-19 Vaccine*</td>
<td>mRNA COVID-19 vaccine BNT162b2 and Original/Omicron BA.4/BA.5-adapted bivalent vaccine have been officially registered as drugs/products (biological products) in Hong Kong and approved as regular imported vaccines in Macau. The related dosage forms for children (for vaccination of children aged 5 to 11) and infants (for vaccination of infants of 6 months to 4 years old) have been authorized for emergency use (EUA) in Hong Kong and special license import in Macau.</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Cardiovascular System</td>
<td>Heparin Series Formulations</td>
<td>The series include enoxaparin sodium injection, heparin sodium injection, low molecular weight heparin for injection and nadroparin calcium injection etc. Heparin series preparations are mainly used for the prevention of thrombosis or treatment of embolism. Fosun Pharma has the full industry chain supply capability for low-grade and high-grade heparin products, low-molecular heparin raw materials and preparations, and the sales network covers China, the United States, South America, Europe, the Middle East and Southeast Asia.</td>
<td></td>
</tr>
</tbody>
</table>

Note*: license-in product
<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Product</th>
<th>Target/MOA</th>
<th>Indication</th>
<th>Pre-Clinical</th>
<th>IND</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>NDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-tumor</td>
<td>HLX10(^1)</td>
<td>+Chemo</td>
<td>PD-1</td>
<td>Squamous non-small cell lung cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Extensive-stage small cell lung cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Metastatic esophageal squamous-cell carcinoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>+Chemo+Radio</td>
<td>PD-1</td>
<td>Neo-/adjuvant treatment of gastric cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Limited-stage small cell lung cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>+Bevacizum</td>
<td>PD-1+VEGF</td>
<td>Non-squamous non-small cell lung cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Metastatic colorectal cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>+HLX07</td>
<td>PD-1+EGFR</td>
<td>Squamous-cell carcinoma of the head and neck</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Squamous non-small cell lung cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>+HLX07+Bevacizum</td>
<td>PD-1+EGFR+VEGF</td>
<td>Hepatocellular carcinoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX07</td>
<td></td>
<td></td>
<td>Solid tumors, Locally advanced or metastatic squamous cell skin cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX22</td>
<td>+Trastuzumab</td>
<td>HER2+HER2</td>
<td>Gastric cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>+Serplulimab+Standard Therapy (Trastuzumab+Chemo)</td>
<td>HER2+PD-1+HER2</td>
<td>Gastric cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX11 (^2)</td>
<td>(Pertuzumab)</td>
<td>HER2</td>
<td>Neo-/adjuvant treatment of breast cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX05 (^3)</td>
<td>(Cetuximab)</td>
<td>EGFR</td>
<td>Metastatic colorectal cancer and squamous-cell carcinoma of the head and neck</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX02 (^4)</td>
<td>(Trastuzumab)</td>
<td>HER2</td>
<td>Breast cancer and metastatic gastric cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note 1: granted KG Bio to develop and commercialize HLX10 in 10 countries in Southeast Asia
Note 2: granted Jingze Biotech to commercialize HLX05 in China
Note 3: last update on 31st July 2023
Note 4: collaborated with Accord, Cipla, Jacobson, mAbxience, Eurofarma, Abbott

Note 1: granted KG Bio to develop and commercialize HLX10 in 10 countries in Southeast Asia
Note 2: granted Organon exclusive global commercialization rights except for China
Note 3: last update on 31st July 2023
Note 4: collaborated with Accord, Cipla, Jacobson, mAbxience, Eurofarma, Abbott
<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Product</th>
<th>Target/OA</th>
<th>Indication</th>
<th>Pre-Clinical</th>
<th>IND</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>NDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-tumor</td>
<td>FS-1502</td>
<td>HER2</td>
<td>HER2-positive advanced malignant solid tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HER2-positive locally advanced or metastatic breast cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>+Serplulimab</td>
<td></td>
<td>HER2+PD-1</td>
<td>HER2-positive advanced gastric cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>±Chemo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX26</td>
<td>LAG-3+PD-1</td>
<td>Metastatic colorectal cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>+Serplulimab</td>
<td></td>
<td>LAG-3+PD-1</td>
<td>Advanced non-small cell lung cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>+Chemo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX301</td>
<td>PD-L1×TIGIT</td>
<td>Solid tumours, lymphomas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>First subject had been dosed in Australia in February 2022; Approved to enter clinical trials by NMPA in March 2022; first subject had been dosed in Chinese Mainland in July 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX15</td>
<td>CD38</td>
<td>Multiple myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>First subject had been dosed in Chinese Mainland in February 2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX13</td>
<td>OX40</td>
<td>Advanced/metastatic solid tumor and lymphoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Ipilimumab)</td>
<td>CTLA-4</td>
<td>Melanoma, renal cell carcinoma and metastatic colorectal cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX53</td>
<td>TIGIT</td>
<td>Solid tumours, lymphomas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX60</td>
<td>GARP</td>
<td>Solid tumours, lymphomas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>First subject had been dosed in China in February 2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood system</td>
<td>Recombinant Human Erythropoietin Injection(pre-filled syringe)</td>
<td>EPO</td>
<td>Anemia of renal disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metabolism and</td>
<td>Recombinant Insulin Glargine Injection</td>
<td>INSR</td>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alimentary System</td>
<td>Mixed Protamine Zinc Recombinant Insulin Lispro Injection (50R)</td>
<td>INSR</td>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Liraglutide Injection</td>
<td>GLP-1</td>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Semaglutide</td>
<td>GLP-1</td>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>HLX04-O¹</td>
<td>VEGF</td>
<td>Wet age-related macular degeneration</td>
<td>Global multi-center clinical trial Ph3; first subject had been dosed in the U.S. in February 2022; first subject had been dosed in Australia, Europe and Chinese Mainland individually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX14  (Denosumab) ²</td>
<td>RANKL</td>
<td>Osteoporosis</td>
<td>Initiated Ph3 clinical trial in Chinese Mainland in June 2022; approved to enter Ph3 clinical trial by TGA in July 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RT002</td>
<td>Bio 1</td>
<td>Moderate to severe glabellar lines in adults (GL)</td>
<td>The NDA was accepted by the NMPA in April 2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GC101</td>
<td>Bio 1</td>
<td>Cervical dystonia (CD)</td>
<td>The NDA was accepted by the NMPA in July 2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SurvVaxM</td>
<td>Survivin</td>
<td>Primary diagnosis of glioblastoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note 1: granted ESSEX an exclusive license to develop, manufacture, and commercialize HLX04 in human ophthalmic therapeutic use
Note 2: granted Organon exclusive global commercialization rights except for China
Note 3: last update on 31st July 2023
<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Product</th>
<th>Target/MOA</th>
<th>Indication</th>
<th>Pre-Clinical</th>
<th>IND</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>NDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-tumor</td>
<td>FCN-437c</td>
<td>CDK4/6</td>
<td>Breast cancer (1L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Breast cancer (2L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>SAF-189</td>
<td>ALK/ROS1</td>
<td>Non-small cell lung cancer (ALK+)</td>
<td>Initiated Phase 3 clinical trial in Chinese Mainland in January 2022; Phase 1 clinical trial in the U.S.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Non-small cell lung cancer (ROS1+)</td>
<td>Approved to enter clinical trials by FDA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HLX-208</td>
<td>BRAF</td>
<td>Solid tumors (metastatic colorectal cancer, non-small cell lung cancer, etc.) LCH and ECD</td>
<td>Granted with the Breakthrough Therapy Designation by the NMPA in April 2023</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>BRAF V600E or BRAF V600 mutation-positive advanced solid tumours (NSCL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FCN-159</td>
<td>MEK</td>
<td>Neurofibromatosis type I</td>
<td>Granted with the Breakthrough Therapy Designation by the NMPA in June 2023; Clinical trial Phase 3 started; Global multi-center clinical trial Phase 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Low-grade glioma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Histiocytic tumor</td>
<td>Granted with the Breakthrough Therapy Designation by the NMPA in April 2023; Approved to enter clinical trials by NMPA in May 2022</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Langerhans cell histiocytosis in children</td>
<td>Approved to enter Phase 2 clinical trial by NMPA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>YP01001</td>
<td>VEGFR</td>
<td>Advanced solid tumor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FCN-338</td>
<td>BCL-2</td>
<td>Myeloid malignancy</td>
<td>Approved to enter Phase 2 clinical trials by NMPA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Hematological malignancy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Relapsed or refractory B-cell lymphoma</td>
<td>Phase 1 clinical trials (included the U.S.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>FH-2001</td>
<td>FGFR/PD-L1</td>
<td>Advanced malignant solid tumour</td>
<td>Phase 1 clinical trials (included the U.S.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORIN1001</td>
<td>IRE1</td>
<td>Solid Tumour</td>
<td>Phase 1 clinical trials (included the U.S.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: last update on 31st July 2023
# Small Molecules Pipeline (2/2)

<table>
<thead>
<tr>
<th>Therapeutic Area</th>
<th>Product</th>
<th>Target/MOA</th>
<th>Indication</th>
<th>Pre-Clinical</th>
<th>IND</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>NDA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood System</strong></td>
<td>Avatrombopag Tablet</td>
<td>TPO-R</td>
<td>Chronic idiopathic thrombocytopenic purpura (ITP)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NDA was accepted by NMPA in December 2022</td>
</tr>
<tr>
<td></td>
<td>Tenapanor Tablet</td>
<td>NHE 3</td>
<td>End-stage Renal Disease – Hemodialysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NDA was accepted by NMPA in July 2023</td>
</tr>
<tr>
<td><strong>Metabolism and Alimentary System</strong></td>
<td>Keverprazan Hydrochloride</td>
<td>P-CAB</td>
<td>Duodenal Ulcer, Reflux Esophagitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Approved to enter Ph1 clinical trials by FDA; Approved in China</td>
</tr>
<tr>
<td></td>
<td>Tenapanor Tablet</td>
<td>NHE 3</td>
<td>Irritable Bowel Syndrome with Constipation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chinese mainland: Ph1 Clinical trials; Hong Kong region: NDA</td>
</tr>
<tr>
<td><strong>Infectious Diseases</strong></td>
<td>PA-824</td>
<td>-</td>
<td>Unable to tolerate treatment/has poor treatment outcomes (XDR-TB) or TB (MDR-TB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Launched Pretomanid in the U.S.*</td>
</tr>
<tr>
<td><strong>Nervous System</strong></td>
<td>Opicapone Tablet</td>
<td>COMT</td>
<td>Parkinson's syndromes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Launched Ongentisy in Europe*</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td>Fortacin spray (Lidocaine Prilocaine spray)</td>
<td>-</td>
<td>Premature ejaculation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Launched in Europe*</td>
</tr>
<tr>
<td></td>
<td>ET-26</td>
<td>-</td>
<td>Anesthesia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Initiated Ph2 clinical trial in Chinese Mainland in July 2022</td>
</tr>
<tr>
<td></td>
<td>FCN-159</td>
<td>MEK</td>
<td>Arteriovenous malformation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORIN1001</td>
<td>IRE1</td>
<td>Idiopathic pulmonary fibrosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Approved to enter clinical trials by NMPA; Ph1 clinical trials in the U.S.</td>
</tr>
<tr>
<td></td>
<td>FCN-016 eye drops</td>
<td>ROCK</td>
<td>Glaucoma or high intraocular pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Approved to enter clinical trials by NMPA in January 2023</td>
</tr>
<tr>
<td></td>
<td>SZEY-2108 for injection</td>
<td>-</td>
<td>CRE infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Approved to enter clinical trials by NMPA in June 2023</td>
</tr>
</tbody>
</table>

Note: last update on 31st July 2023
## Vaccine Pipeline

<table>
<thead>
<tr>
<th>Product</th>
<th>Technology</th>
<th>Pre-Clinical</th>
<th>IND</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>NDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Freeze-dried Human Rabies Vaccine (Vero Cells)</td>
<td>Inactivated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-Valent Influenza Vaccine</td>
<td>Inactivated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Diploid Cell Rabies Vaccine</td>
<td>Inactivated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13-Valent Pneumococcal Conjugate Vaccine</td>
<td>Multivalent Conjugate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24-Valent Pneumococcal Conjugate Vaccine</td>
<td>Multivalent Conjugate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23-Valent Pneumococcal Conjugate Vaccine</td>
<td>Multivalent Conjugate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadrivalent Meningococcal Polysaccharide Vaccine</td>
<td>Multivalent Conjugate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus Vaccine</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quadravalent Meningococcal Conjugate Vaccine</td>
<td>Multivalent Conjugate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recombinant Zoster Vaccine</td>
<td>Insect Cells with Recombinant Baculovirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recombinant Quadravalent Influenza Vaccine</td>
<td>Insect Cells with Recombinant Baculovirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: last update on 31st July 2023
免责条款及商标版权

• 本文件中所包含的所有内容（包括预测性描述），复星医药、陈述人或提供人不保证其完全准确、完整或及时，如因有关内容存在错误、遗漏或失准之处而引致的行为或结果，复星医药、陈述人或提供人对此不承担责任。

• 本文件内容不包含亦不应被视为任何投资建议，投资者基于本文件中内容做出的投资决策，责任自负。

• 本文件及其中所包含内容的所有权利包括版权均由复星医药独家所有，其中相关的“FOSUN”和“复星”字样、图案及相关LOGO标识均为复星医药合法所有的字号、商标和标识。该等资料和内容未经复星医药书面同意，任何第三方不得以包括转载在内的任何方式加以使用。

• Fosun Pharma, the Representor or the Provider will not warrant the accuracy, the completeness and the timeliness of all information and contents, including predictive description, contained in the PPT documents/visual materials. In the event of any mistake, omission, and inaccuracy, Fosun Pharma, the Representor or the Provider should not be held for any liabilities in this regard.

• The PPT documents/visual materials will not include and should not be deemed as any investment proposals. The investor should take their own responsibilities for any determinations so come to based upon the information contained in the PPT documents/visual materials.

• Fosun Pharma is entitled to all rights, including copyright, pertaining to the PPT documents/visual materials. The characters, the designs and other related logos, like “Fosun” and“复星”， are the trade name, trademark and the logos legally owned by Fosun Pharma. Without written consent offered by Fosun Pharma, any third party should not utilize such materials and information in any manner, including reprinting.